ReviewClinical reviews in allergy & immunology2012
The therapeutic potential of epigenetics in autoimmune diseases.
Review in Clinical reviews in allergy & immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Cytokine gene considerations in giant cell arteritis: IL10 promoter polymorphisms and a review of the literature.Clinical reviews in allergy & immunology · 2014Pooled it
- The Interplay of Autoimmune Disease, Cancer, and Immunity: Current Understanding and Therapeutic Prospects.International journal of hematology-oncology and stem cell research · 2025Review
- Immunomics in Pediatric Rheumatic Diseases.Frontiers in medicine · 2019Review
- Epigenetics and Primary Biliary Cirrhosis: a Comprehensive Review and Implications for Autoimmunity.Clinical reviews in allergy & immunology · 2016Review
- Genes affecting β-cell function in type 1 diabetes.Current diabetes reports · 2015Review
- Multicentric reticulohistiocytosis: a critical review.Current rheumatology reports · 2015Review
- Multiple Sclerosis Risk Allele in CLEC16A Acts as an Expression Quantitative Trait Locus for CLEC16A and SOCS1 in CD4+ T Cells.PloS one · 2015Article
- The challenge of treating orphan disease.Clinical reviews in allergy & immunology · 2014Article
- Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?Nature reviews. Rheumatology · 2014Review
- Unmet needs in autoimmunity and potential new tools.Clinical reviews in allergy & immunology · 2014Review
- Molecular mechanisms in autoimmune type 1 diabetes: a critical review.Clinical reviews in allergy & immunology · 2014Review
- MicroRNAs in lupus.Autoimmunity · 2014Review
- Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE.Nature reviews. Rheumatology · 2014Review
- Open questions in autoimmunity: discussions from the 2013 Controversies in Rheumatology and Autoimmunity Meeting.BMC medicine · 2014Article
- Hypomethylation and overexpression of ITGAL (CD11a) in CD4(+) T cells in systemic sclerosis.Clinical epigenetics · 2014Article
- Autoimmunity in 2012.Clinical reviews in allergy & immunology · 2013Review
- Everything is autoimmune until proven otherwise.Clinical reviews in allergy & immunology · 2013Review
- Can rheumatoid arthritis be prevented?Best practice & research. Clinical rheumatology · 2013Review
- Beyond gene discovery in inflammatory bowel disease: the emerging role of epigenetics.Gastroenterology · 2013Review
- Autoimmune features in metabolic liver disease: a single-center experience and review of the literature.Clinical reviews in allergy & immunology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune diseases now include over 100 conditions and are estimated to affect over 20 million people in the United States or 5% of the world population with numerous geographical differences coined as geoepidemiology. Further, concordance rates in monozygotic twins are significantly higher compared to dizygotic sets while being significantly below 50% for most autoimmune diseases. These lines of evidence suggest that additional mechanisms are needed to link the individual susceptibility with the proposed chemical and infectious factors in the environment. Epigenetics may well constitute this missing link to include DNA methylation, histone changes, and microRNA which contribute to the epigenome characterizing specific diseases. Importantly, these epigenetic changes may be ideal targets for new personalized treatments as suggested by data in cancer. A number of chemical and physical factors, along with proposed infectious agents or aging, are involved in the etiopathogenesis of autoimmune diseases through epigenetic changes. The most prominent evidence on the association between environment and autoimmunity has been reported in systemic lupus erythematosus, but similar mechanisms were proposed in rheumatoid arthritis, systemic sclerosis, and type 1 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.